# Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/lenvatinib-plus-sintilimab-versus-lenvatinib-monotherapy-as-first-line-treatment/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Lei Zhao,Nijia Chang,Lei Shi,Fengyi Li,Fanglin Meng,Xiaohui Xie,Zhe Xu,Fu‐Sheng Wang |
| Citations | 25 |
| DOI | 10.1016/j.heliyon.2022.e09538 |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | http://www.cell.com/article/S240584402200826X/pdf |
| OpenAlex ID | https://openalex.org/W4281568632 |
| PMID | 35706954 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Xiaohui Xie](https://scholariq.org/researchers/xiaohui-xie/)

## Paper journal

- [Heliyon](https://scholariq.org/journals/heliyon/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Hepatitis B Virus Studies](https://scholariq.org/topics/hepatitis-b-virus-studies/)
- [Cancer Mechanisms and Therapy](https://scholariq.org/topics/cancer-mechanisms-and-therapy/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.